Subjects -> MEDICAL SCIENCES (Total: 8642 journals)
    - ALLERGOLOGY AND IMMUNOLOGY (218 journals)
    - ANAESTHESIOLOGY (120 journals)
    - CARDIOVASCULAR DISEASES (338 journals)
    - CHIROPRACTIC, HOMEOPATHY, OSTEOPATHY (21 journals)
    - COMMUNICABLE DISEASES, EPIDEMIOLOGY (234 journals)
    - DENTISTRY (293 journals)
    - DERMATOLOGY AND VENEREOLOGY (164 journals)
    - EMERGENCY AND INTENSIVE CRITICAL CARE (121 journals)
    - ENDOCRINOLOGY (150 journals)
    - FORENSIC SCIENCES (42 journals)
    - GASTROENTEROLOGY AND HEPATOLOGY (188 journals)
    - GERONTOLOGY AND GERIATRICS (138 journals)
    - HEMATOLOGY (157 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (174 journals)
    - LABORATORY AND EXPERIMENTAL MEDICINE (99 journals)
    - MEDICAL GENETICS (58 journals)
    - MEDICAL SCIENCES (2392 journals)
    - NURSES AND NURSING (364 journals)
    - OBSTETRICS AND GYNECOLOGY (207 journals)
    - ONCOLOGY (384 journals)
    - OPHTHALMOLOGY AND OPTOMETRY (140 journals)
    - ORTHOPEDICS AND TRAUMATOLOGY (170 journals)
    - OTORHINOLARYNGOLOGY (83 journals)
    - PATHOLOGY (100 journals)
    - PEDIATRICS (275 journals)
    - PHYSICAL MEDICINE AND REHABILITATION (158 journals)
    - PSYCHIATRY AND NEUROLOGY (833 journals)
    - RADIOLOGY AND NUCLEAR MEDICINE (192 journals)
    - RESPIRATORY DISEASES (104 journals)
    - RHEUMATOLOGY (79 journals)
    - SPORTS MEDICINE (81 journals)
    - SURGERY (406 journals)
    - UROLOGY, NEPHROLOGY AND ANDROLOGY (155 journals)

CARDIOVASCULAR DISEASES (338 journals)                  1 2 | Last

Showing 1 - 200 of 338 Journals sorted alphabetically
Acta Angiologica     Open Access   (Followers: 5)
Acta Cardiologica     Hybrid Journal   (Followers: 2)
Acute Cardiac Care     Hybrid Journal   (Followers: 8)
Adipositas - Ursachen, Folgeerkrankungen, Therapie     Hybrid Journal  
AJP Heart and Circulatory Physiology     Hybrid Journal   (Followers: 12)
Aktuelle Kardiologie     Hybrid Journal   (Followers: 1)
American Heart Journal     Hybrid Journal   (Followers: 60)
American Journal of Cardiology     Hybrid Journal   (Followers: 68)
American Journal of Cardiovascular Drugs     Hybrid Journal   (Followers: 17)
American Journal of Hypertension     Hybrid Journal   (Followers: 28)
Anales de Cirugia Vascular     Full-text available via subscription   (Followers: 1)
Anatolian Journal of Cardiology     Open Access   (Followers: 6)
Angiología     Full-text available via subscription  
Angiologia e Cirurgia Vascular     Open Access   (Followers: 1)
Angiology     Hybrid Journal   (Followers: 3)
Annales de Cardiologie et d'Angéiologie     Full-text available via subscription   (Followers: 1)
Annals of Circulation     Open Access   (Followers: 2)
Annals of Noninvasive Electrocardiology     Hybrid Journal   (Followers: 1)
Annals of Pediatric Cardiology     Open Access   (Followers: 12)
AORTA     Open Access  
Archives of Cardiovascular Diseases     Full-text available via subscription   (Followers: 5)
Archives of Cardiovascular Diseases Supplements     Full-text available via subscription   (Followers: 3)
Archives of Cardiovascular Imaging     Open Access   (Followers: 2)
Archivos de cardiología de México     Open Access   (Followers: 1)
Argentine Journal of Cardiology (English edition)     Open Access   (Followers: 2)
Arquivos Brasileiros de Cardiologia     Open Access   (Followers: 2)
Arrhythmia & Electrophysiology Review     Open Access   (Followers: 1)
Arteriosclerosis, Thrombosis and Vascular Biology     Full-text available via subscription   (Followers: 32)
Artery Research     Hybrid Journal   (Followers: 4)
ARYA Atherosclerosis     Open Access  
ASAIO Journal     Hybrid Journal   (Followers: 3)
ASEAN Heart Journal     Open Access   (Followers: 2)
Asian Cardiovascular and Thoracic Annals     Hybrid Journal   (Followers: 2)
Aswan Heart Centre Science & Practice Services     Open Access   (Followers: 1)
Atherosclerosis : X     Open Access  
Bangladesh Heart Journal     Open Access   (Followers: 3)
Basic Research in Cardiology     Hybrid Journal   (Followers: 10)
BMC Cardiovascular Disorders     Open Access   (Followers: 22)
Brain Circulation     Open Access   (Followers: 1)
British Journal of Cardiology     Full-text available via subscription   (Followers: 18)
Canadian Journal of Cardiology     Hybrid Journal   (Followers: 18)
Cardiac Cath Lab Director     Full-text available via subscription  
Cardiac Electrophysiology Review     Hybrid Journal   (Followers: 2)
Cardiac Failure Review     Open Access   (Followers: 1)
Cardiocore     Full-text available via subscription   (Followers: 1)
Cardiogenetics     Open Access   (Followers: 3)
Cardiology     Full-text available via subscription   (Followers: 20)
Cardiology and Angiology: An International Journal     Open Access   (Followers: 1)
Cardiology and Therapy     Open Access   (Followers: 12)
Cardiology Clinics     Full-text available via subscription   (Followers: 14)
Cardiology in Review     Hybrid Journal   (Followers: 8)
Cardiology in the Young     Hybrid Journal   (Followers: 34)
Cardiology Journal     Open Access   (Followers: 6)
Cardiology Plus     Open Access   (Followers: 1)
Cardiology Research     Open Access   (Followers: 15)
Cardiology Research and Practice     Open Access   (Followers: 10)
Cardiopulmonary Physical Therapy Journal     Hybrid Journal   (Followers: 8)
Cardiorenal Medicine     Full-text available via subscription   (Followers: 1)
Cardiothoracic Surgeon     Open Access   (Followers: 1)
CardioVasc     Full-text available via subscription   (Followers: 1)
Cardiovascular & Haematological Disorders - Drug Targets     Hybrid Journal   (Followers: 1)
Cardiovascular & Hematological Agents in Medicinal Chemistry     Hybrid Journal   (Followers: 2)
CardioVascular and Interventional Radiology     Hybrid Journal   (Followers: 15)
Cardiovascular and Thoracic Open     Open Access  
Cardiovascular Diabetology     Open Access   (Followers: 10)
Cardiovascular Drugs and Therapy     Hybrid Journal   (Followers: 14)
Cardiovascular Endocrinology & Metabolism     Hybrid Journal   (Followers: 1)
Cardiovascular Engineering     Hybrid Journal   (Followers: 1)
Cardiovascular Engineering and Technology     Hybrid Journal   (Followers: 1)
Cardiovascular Intervention and Therapeutics     Hybrid Journal   (Followers: 5)
Cardiovascular Journal     Open Access   (Followers: 6)
Cardiovascular Journal of Africa     Full-text available via subscription   (Followers: 5)
Cardiovascular Journal of South Africa     Full-text available via subscription   (Followers: 1)
Cardiovascular Medicine in General Practice     Full-text available via subscription   (Followers: 7)
Cardiovascular Pathology     Hybrid Journal   (Followers: 4)
Cardiovascular Regenerative Medicine     Open Access  
Cardiovascular Research     Hybrid Journal   (Followers: 15)
Cardiovascular Revascularization Medicine     Hybrid Journal   (Followers: 1)
Cardiovascular System     Open Access  
Cardiovascular Therapeutics     Open Access   (Followers: 1)
Cardiovascular Toxicology     Hybrid Journal   (Followers: 6)
Cardiovascular Ultrasound     Open Access   (Followers: 5)
Case Reports in Cardiology     Open Access   (Followers: 7)
Catheterization and Cardiovascular Interventions     Hybrid Journal   (Followers: 3)
Cerebrovascular Diseases     Full-text available via subscription   (Followers: 3)
Cerebrovascular Diseases Extra     Open Access  
Chest     Full-text available via subscription   (Followers: 103)
Choroby Serca i Naczyń     Open Access   (Followers: 1)
Circulation     Hybrid Journal   (Followers: 265)
Circulation : Cardiovascular Imaging     Hybrid Journal   (Followers: 15)
Circulation : Cardiovascular Interventions     Hybrid Journal   (Followers: 19)
Circulation : Cardiovascular Quality and Outcomes     Hybrid Journal   (Followers: 11)
Circulation : Genomic and Precision Medicine     Hybrid Journal   (Followers: 16)
Circulation : Heart Failure     Hybrid Journal   (Followers: 26)
Circulation Research     Hybrid Journal   (Followers: 36)
Cirugía Cardiovascular     Open Access  
Clínica e Investigación en Arteriosclerosis     Full-text available via subscription  
Clínica e Investigación en arteriosclerosis (English Edition)     Hybrid Journal  
Clinical and Experimental Hypertension     Hybrid Journal   (Followers: 3)
Clinical Cardiology     Hybrid Journal   (Followers: 11)
Clinical Hypertension     Open Access   (Followers: 5)
Clinical Medicine Insights : Cardiology     Open Access   (Followers: 6)
Clinical Research in Cardiology     Hybrid Journal   (Followers: 6)
Clinical Research in Cardiology Supplements     Hybrid Journal  
Clinical Trials and Regulatory Science in Cardiology     Open Access   (Followers: 4)
Congenital Heart Disease     Hybrid Journal   (Followers: 6)
Congestive Heart Failure     Hybrid Journal   (Followers: 4)
Cor et Vasa     Full-text available via subscription   (Followers: 1)
Coronary Artery Disease     Hybrid Journal   (Followers: 2)
CorSalud     Open Access  
Critical Pathways in Cardiology     Hybrid Journal   (Followers: 4)
Current Cardiology Reports     Hybrid Journal   (Followers: 7)
Current Cardiology Reviews     Hybrid Journal   (Followers: 4)
Current Cardiovascular Imaging Reports     Hybrid Journal   (Followers: 1)
Current Cardiovascular Risk Reports     Hybrid Journal  
Current Heart Failure Reports     Hybrid Journal   (Followers: 5)
Current Hypertension Reports     Hybrid Journal   (Followers: 6)
Current Hypertension Reviews     Hybrid Journal   (Followers: 6)
Current Opinion in Cardiology     Hybrid Journal   (Followers: 14)
Current Problems in Cardiology     Hybrid Journal   (Followers: 3)
Current Research : Cardiology     Full-text available via subscription   (Followers: 1)
Current Treatment Options in Cardiovascular Medicine     Hybrid Journal   (Followers: 1)
Current Vascular Pharmacology     Hybrid Journal   (Followers: 5)
CVIR Endovascular     Open Access   (Followers: 1)
Der Kardiologe     Hybrid Journal   (Followers: 2)
Echo Research and Practice     Open Access   (Followers: 2)
Echocardiography     Hybrid Journal   (Followers: 4)
Egyptian Heart Journal     Open Access   (Followers: 2)
Egyptian Journal of Cardiothoracic Anesthesia     Open Access  
ESC Heart Failure     Open Access   (Followers: 4)
European Cardiology Review     Open Access   (Followers: 1)
European Heart Journal     Hybrid Journal   (Followers: 68)
European Heart Journal - Cardiovascular Imaging     Hybrid Journal   (Followers: 10)
European Heart Journal - Cardiovascular Pharmacotherapy     Full-text available via subscription   (Followers: 2)
European Heart Journal - Quality of Care and Clinical Outcomes     Hybrid Journal  
European Heart Journal : Acute Cardiovascular Care     Hybrid Journal   (Followers: 1)
European Heart Journal : Case Reports     Open Access   (Followers: 1)
European Heart Journal Supplements     Hybrid Journal   (Followers: 8)
European Journal of Cardio-Thoracic Surgery     Hybrid Journal   (Followers: 9)
European Journal of Cardio-Thoracic Surgery Supplements     Full-text available via subscription   (Followers: 2)
European Journal of Cardiovascular Nursing     Hybrid Journal   (Followers: 5)
European Journal of Heart Failure     Hybrid Journal   (Followers: 14)
European Journal of Preventive Cardiology.     Hybrid Journal   (Followers: 6)
European Stroke Organisation     Hybrid Journal   (Followers: 3)
Experimental & Translational Stroke Medicine     Open Access   (Followers: 9)
Expert Review of Cardiovascular Therapy     Full-text available via subscription   (Followers: 3)
Folia Cardiologica     Open Access  
Forum Zaburzeń Metabolicznych     Hybrid Journal  
Frontiers in Cardiovascular Medicine     Open Access   (Followers: 1)
Future Cardiology     Hybrid Journal   (Followers: 6)
General Thoracic and Cardiovascular Surgery     Hybrid Journal   (Followers: 3)
Global Cardiology Science and Practice     Open Access   (Followers: 5)
Global Heart     Hybrid Journal   (Followers: 3)
Heart     Hybrid Journal   (Followers: 48)
Heart and Mind     Open Access  
Heart and Vessels     Hybrid Journal  
Heart Failure Clinics     Full-text available via subscription   (Followers: 2)
Heart Failure Reviews     Hybrid Journal   (Followers: 3)
Heart India     Open Access   (Followers: 2)
Heart International     Full-text available via subscription  
Heart Rhythm     Hybrid Journal   (Followers: 11)
Heart Views     Open Access   (Followers: 2)
HeartRhythm Case Reports     Open Access  
Hellenic Journal of Cardiology     Open Access   (Followers: 1)
Herz     Hybrid Journal   (Followers: 3)
High Blood Pressure & Cardiovascular Prevention     Full-text available via subscription   (Followers: 2)
Hypertension     Full-text available via subscription   (Followers: 23)
Hypertension     Open Access   (Followers: 2)
Hypertension in Pregnancy     Hybrid Journal   (Followers: 9)
Hypertension Research     Hybrid Journal   (Followers: 4)
Ibrahim Cardiac Medical Journal     Open Access  
IJC Heart & Vessels     Open Access   (Followers: 1)
IJC Heart & Vasculature     Open Access   (Followers: 1)
IJC Metabolic & Endocrine     Open Access   (Followers: 1)
Indian Heart Journal     Open Access   (Followers: 5)
Indian Journal of Cardiovascular Disease in Women WINCARS     Open Access  
Indian Journal of Thoracic and Cardiovascular Surgery     Hybrid Journal  
Indian Pacing and Electrophysiology Journal     Open Access   (Followers: 1)
Innovations : Technology and Techniques in Cardiothoracic and Vascular Surgery     Hybrid Journal   (Followers: 1)
Insuficiencia Cardíaca     Open Access  
Interactive CardioVascular and Thoracic Surgery     Hybrid Journal   (Followers: 7)
International Cardiovascular Forum Journal     Open Access  
International Journal of Angiology     Hybrid Journal   (Followers: 2)
International Journal of Cardiology     Hybrid Journal   (Followers: 18)
International Journal of Cardiology Hypertension     Open Access   (Followers: 1)
International Journal of Cardiovascular and Cerebrovascular Disease     Open Access   (Followers: 2)
International Journal of Cardiovascular Imaging     Hybrid Journal   (Followers: 2)
International Journal of Cardiovascular Research     Hybrid Journal   (Followers: 6)
International Journal of Heart Rhythm     Open Access  
International Journal of Hypertension     Open Access   (Followers: 8)
International Journal of Hyperthermia     Open Access  
International Journal of Stroke     Hybrid Journal   (Followers: 32)
International Journal of the Cardiovascular Academy     Open Access  
Interventional Cardiology Clinics     Full-text available via subscription   (Followers: 2)
Interventional Cardiology Review     Open Access  
JACC : Basic to Translational Science     Open Access   (Followers: 5)
JACC : Cardiovascular Imaging     Hybrid Journal   (Followers: 18)
JACC : Cardiovascular Interventions     Hybrid Journal   (Followers: 19)
JACC : Heart Failure     Full-text available via subscription   (Followers: 14)
JAMA Cardiology     Hybrid Journal   (Followers: 30)

        1 2 | Last

Similar Journals
Journal Cover
European Heart Journal
Journal Prestige (SJR): 9.315
Citation Impact (citeScore): 9
Number of Followers: 68  
 
  Hybrid Journal Hybrid journal (It can contain Open Access articles)
ISSN (Print) 0195-668X - ISSN (Online) 1522-9645
Published by Oxford University Press Homepage  [412 journals]
  • From TAVI to tricuspid cliping: fine-tuning the management of valvular
           heart disease
    • Authors: Lüscher T.
      Pages: 1863 - 1866
      PubDate: Thu, 21 May 2020 00:00:00 GMT
      DOI: 10.1093/eurheartj/ehaa459
      Issue No: Vol. 41, No. 20 (2020)
       
  • The Eyes on the Nobel PrizeGöran K. Hansson speaks to CardioPulse about
           the Nobel honours and what makes a Nobel Prize winner
    • Authors: Ozkan J.
      Pages: 1867 - 1869
      PubDate: Thu, 21 May 2020 00:00:00 GMT
      DOI: 10.1093/eurheartj/ehaa198
      Issue No: Vol. 41, No. 20 (2020)
       
  • The ESC Working Group on Adult Congenital Heart DiseaseThe Working Group
           goals to improve the management, quality of life and outcome for the ever
           increasing number of adults with congenital heart disease are discussed
    • Authors: Gatzoulis M; Diller G, Budts W, et al.
      Pages: 1870 - 1871
      Abstract: Congenital heart disease (CHD) is one of the truly successful stories of modern cardiology and medicine enabling an ever-increasing number of patients, including those with complex CHD, to reach adulthood and enjoy good quality of life. Accordingly, the number of adult patients with CHD is constantly increasing, hence there are now more adult than paediatric patients with CHD receiving and benefiting from specialist care. At the same time, it is widely accepted that true correction of CHD is seldomly achieved, with most patients requiring lifelong care and tertiary expertise. Consequently, there are ongoing pressures for resource allocation, education and training, and creating/increasing capacity to provide for the adult with CHD in Europe and beyond.
      PubDate: Thu, 21 May 2020 00:00:00 GMT
      DOI: 10.1093/eurheartj/ehaa323
      Issue No: Vol. 41, No. 20 (2020)
       
  • COVID-19 and congenital heart disease in perspectiveA short report on
           health, patients and well-being, by Michael A. Gatzoulis in London
    • Authors: Gatzoulis M.
      Pages: 1871 - 1872
      Abstract: Cycling to work in London now feels surreal: very few people about, a metropolis stripped of its many attractions (museums, restaurants, shops, etc.), but buildings and other material objects remain intact. It is only people who are affected. Uncertainty looms large on relaxing the draconian measures taken to slow down the spread of the disease, so we can return to some ‘normality’. Last, but not least, legitimate concerns are about the economic and psychosocial implications of the pandemic, and the consequent disruption of the societal fabric, as we know it.
      PubDate: Fri, 08 May 2020 00:00:00 GMT
      DOI: 10.1093/eurheartj/ehaa407
      Issue No: Vol. 41, No. 20 (2020)
       
  • Heart Team meetings during COVID-19Different formats of multidisciplinary
           Heart Team meetings under the gathering restriction rules due to the
           coronavirus disease-2019 pandemic are discussed
    • Authors: Wahadat A; Sadeghi A, Tanis W.
      Pages: 1872 - 1874
      PubDate: Thu, 21 May 2020 00:00:00 GMT
      DOI: 10.1093/eurheartj/ehaa412
      Issue No: Vol. 41, No. 20 (2020)
       
  • CardioEgypt 2020Report from The Egyptian Society of Cardiology (EgSC) 47th
           Annual Meeting in Cairo, Egypt 24–27 February 2020
    • Authors: El Sayed M; Abdelhamid M.
      Pages: 1874 - 1875
      Abstract: Since its establishment in 1951, the EgSC has had a clear vision to help preventing and treating CVD all over Egypt through advocacy, education, research, and patient awareness programs.
      PubDate: Thu, 21 May 2020 00:00:00 GMT
      DOI: 10.1093/eurheartj/ehaa338
      Issue No: Vol. 41, No. 20 (2020)
       
  • Long-term clinical outcome and performance of transcatheter aortic valve
           replacement with a self-expandable bioprosthesis
    • Authors: Testa L; Latib A, Brambilla N, et al.
      Pages: 1876 - 1886
      Abstract: AbstractAims In the last decade, transcatheter aortic valve (TAV) replacement determined a paradigm shift in the treatment of patients with severe symptomatic aortic stenosis. Data on long-term TAV performance are still limited. We sought to evaluate the clinical and haemodynamic outcomes of the CoreValve self-expandable valve up to 8-year follow-up (FU).Methods and results Nine hundred and ninety inoperable or high-risk patients were treated with the CoreValve TAV in eight Italian Centres from June 2007 to December 2011. The median FU was 4.4 years (interquartile range 1.4–6.7 years). Longest FU reached 11 years. A total of 728 died within 8-year FU (78.3% mortality from Kaplan–Meier curve analysis). A significant functional improvement was observed in the majority of patients and maintained over time, with 79.3% of surviving patients still classified New York Heart Association class ≤ II at 8 years. Echocardiographic data showed that the mean transprosthetic aortic gradient remained substantially unchanged (9 ± 4 mmHg at discharge, 9 ± 5 mmHg at 8 years, P = 0.495). The rate of Grade 0/1 paravalvular leak was consistent during FU with no significant change from post-procedure to FU ≥5 years in paired analysis (P = 0.164). Structural valve deterioration (SVD) and late bioprosthetic valve failure (BVF) were defined according to a modification of the 2017 EAPCI/ESC/EACTS criteria. In cumulative incidence functions at 8 years, moderate and severe SVD were 3.0% [95% confidence interval (CI) 2.1–4.3%] and 1.6% (95% CI 0.6–3.9%), respectively, while late BVF was 2.5% (95% CI 1.2–5%).Conclusion While TAVs are questioned about long-term performance and durability, the results of the present research provide reassuring 8-year evidence on the CoreValve first-generation self-expandable bioprosthesis.
      PubDate: Mon, 06 Jan 2020 00:00:00 GMT
      DOI: 10.1093/eurheartj/ehz925
      Issue No: Vol. 41, No. 20 (2020)
       
  • Durability of transcatheter bioprosthetic aortic valves
    • Authors: Sondergaard L.
      Pages: 1887 - 1889
      Abstract: This editorial refers to ‘Long-term clinical outcome and performance of transcatheter aortic valve replacement with a self-expandable bioprostheses’††, by L. Testa et al., on page 1876.
      PubDate: Mon, 06 Jan 2020 00:00:00 GMT
      DOI: 10.1093/eurheartj/ehz890
      Issue No: Vol. 41, No. 20 (2020)
       
  • Comparison of newer generation self-expandable vs. balloon-expandable
           valves in transcatheter aortic valve implantation: the randomized
           SOLVE-TAVI trial
    • Authors: Thiele H; , Kurz T, et al.
      Pages: 1890 - 1899
      Abstract: AbstractAimsTranscatheter aortic valve implantation (TAVI) has emerged as established treatment option in patients with symptomatic aortic stenosis. Technical developments in valve design have addressed previous limitations such as suboptimal deployment, conduction disturbances, and paravalvular leakage. However, there are only limited data available for the comparison of newer generation self-expandable valve (SEV) and balloon-expandable valve (BEV).Methods and resultsSOLVE-TAVI is a multicentre, open-label, 2 × 2 factorial, randomized trial of 447 patients with aortic stenosis undergoing transfemoral TAVI comparing SEV (Evolut R, Medtronic Inc., Minneapolis, MN, USA) with BEV (Sapien 3, Edwards Lifesciences, Irvine, CA, USA). The primary efficacy composite endpoint of all-cause mortality, stroke, moderate/severe prosthetic valve regurgitation, and permanent pacemaker implantation at 30 days was powered for equivalence (equivalence margin 10% with significance level 0.05). The primary composite endpoint occurred in 28.4% of SEV patients and 26.1% of BEV patients meeting the prespecified criteria of equivalence [rate difference −2.39 (90% confidence interval, CI −9.45 to 4.66); Pequivalence = 0.04]. Event rates for the individual components were as follows: all-cause mortality 3.2% vs. 2.3% [rate difference −0.93 (90% CI −4.78 to 2.92); Pequivalence < 0.001], stroke 0.5% vs. 4.7% [rate difference 4.20 (90% CI 0.12 to 8.27); Pequivalence = 0.003], moderate/severe paravalvular leak 3.4% vs. 1.5% [rate difference −1.89 (90% CI −5.86 to 2.08); Pequivalence = 0.0001], and permanent pacemaker implantation 23.0% vs. 19.2% [rate difference −3.85 (90% CI −10.41 to 2.72) in SEV vs. BEV patients; Pequivalence = 0.06].ConclusionIn patients with aortic stenosis undergoing transfemoral TAVI, newer generation SEV and BEV are equivalent for the primary valve-related efficacy endpoint. These findings support the safe application of these newer generation percutaneous valves in the majority of patients with some specific preferences based on individual valve anatomy.
      PubDate: Wed, 12 Feb 2020 00:00:00 GMT
      DOI: 10.1093/eurheartj/ehaa036
      Issue No: Vol. 41, No. 20 (2020)
       
  • Balloon-expandable or self-expandable transcatheter heart valves. Which
           are best'
    • Authors: Webb J; Wood D, Sathananthan J, et al.
      Pages: 1900 - 1902
      Abstract: This editorial refers to ‘Comparison of newer generation self-expandable vs. balloon-expandable valves in transcatheter aortic valve implantation: the randomized SOLVE-TAVI trial’††, by H. Thiele et al., on page 1890.
      PubDate: Tue, 07 Apr 2020 00:00:00 GMT
      DOI: 10.1093/eurheartj/ehaa167
      Issue No: Vol. 41, No. 20 (2020)
       
  • Impact of myocardial fibrosis on left ventricular remodelling, recovery,
           and outcome after transcatheter aortic valve implantation in different
           haemodynamic subtypes of severe aortic stenosis
    • Authors: Puls M; Beuthner B, Topci R, et al.
      Pages: 1903 - 1914
      Abstract: AbstractAims Myocardial fibrosis (MF) might represent a key player in pathophysiology of heart failure in aortic stenosis (AS). We aimed to assess its impact on left ventricular (LV) remodelling, recovery, and mortality after transcatheter aortic valve implantation (TAVI) in different AS subtypes.Methods and results One hundred patients with severe AS were prospectively characterized clinically and echocardiographically at baseline (BL), 6 months, 1 year, and 2 years following TAVI. Left ventricular biopsies were harvested after valve deployment. Myocardial fibrosis was assessed after Masson’s trichrome staining, and fibrotic area was calculated as percentage of total tissue area. Patients were stratified according to MF above (MF+) or below (MF−) median percentage MF (≥11% or <11%). Myocardial fibrosis burden differed significantly between AS subtypes, with highest levels in low ejection fraction (EF), low-gradient AS and lowest levels in normal EF, high-gradient AS (29.5 ± 26.4% vs. 13.5 ± 16.1%, P = 0.003). In the entire cohort, MF+ was significantly associated with poorer LV function, higher extent of pathological LV remodelling, and more pronounced clinical heart failure at BL. After TAVI, MF+ was associated with a delay in normalization of LV geometry and function but not per se with absence of reverse remodelling and clinical improvement. However, 22 patients died during follow-up (mean, 11 months), and 14 deaths were classified as cardiovascular (CV) (n = 9 arrhythmia-associated). Importantly, 13 of 14 CV deaths occurred in MF+ patients (CV mortality 26.5% in MF+ vs. 2% in MF− patients, P = 0.0003). Multivariate analysis identified MF+ as independent predictor of CV mortality [hazard ratio (HR) 27.4 (2.0–369), P = 0.01].Conclusion Histological MF is associated with AS-related pathological LV remodelling and independently predicts CV mortality after TAVI.
      PubDate: Wed, 12 Feb 2020 00:00:00 GMT
      DOI: 10.1093/eurheartj/ehaa033
      Issue No: Vol. 41, No. 20 (2020)
       
  • Left ventricular myocardial fibrosis: a marker of bad prognosis in
           symptomatic severe aortic stenosis
    • Authors: Kong W; Bax J, Delgado V.
      Pages: 1915 - 1917
      Abstract: This editorial refers to ‘Impact of myocardial fibrosis on left ventricular remodelling, recovery, and outcome after transcatheter aortic valve implantation in different haemodynamic subtypes of severe aortic stenosis’††, by M. Puls et al., on page 1903.
      PubDate: Tue, 24 Mar 2020 00:00:00 GMT
      DOI: 10.1093/eurheartj/ehaa151
      Issue No: Vol. 41, No. 20 (2020)
       
  • Functional tricuspid regurgitation of degenerative mitral valve disease: a
           crucial determinant of survival
    • Authors: Essayagh B; Antoine C, Benfari G, et al.
      Pages: 1918 - 1929
      Abstract: AbstractAims To assess functional tricuspid regurgitation (FTR) determinants, consequences, and independent impact on outcome in degenerative mitral regurgitation (DMR).Methods and results All patients diagnosed with isolated DMR 2003–2011, with structurally normal tricuspid leaflets, prospective FTR grading and systolic pulmonary artery pressure (sPAP) estimation by Doppler echocardiography at diagnosis were identified and long-term outcome analysed. The 5083 DMR eligible patients [63 ± 16 years, 47% female, ejection fraction (EF) 63 ± 7%, and sPAP 35 ± 13 mmHg] presented with FTR graded trivial in 45%, mild in 37%, moderate in 15%, and severe in 3%. While pulmonary hypertension (PHTN-sPAP ≥ 50 mmHg) was the most powerful FTR severity determinant, other strong FTR determinants were older age, female sex, lower left ventricle EF, DMR, and particularly atrial fibrillation (AFib) (all P ≤ 0.002). Functional tricuspid regurgitation moderate/severe was independently linked to more severe clinical presentation, more oedema, lower stroke volume, and impaired renal function (P ≤ 0.01). Survival (95% confidence interval) throughout follow-up [70% (69–72%) at 10 years] was strongly associated with FTR severity [82% (80–84%) for trivial, 69% (66–71%) for mild, 51% (47–57%) for moderate, and 26% (19–35%) for severe, P < 0.0001]. Excess mortality persisted after comprehensive adjustment [adjusted hazard ratio 1.40 (1.18–1.67) for moderate FTR and 2.10 (1.63–2.70) for severe FTR, P ≤ 0.01]. Excess mortality persisted adjusting for sPAP/right ventricular function (P < 0.0001), by matching [adjusted hazard ratios 2.08 (1.50–2.89), P < 0.0001] and vs. expected survival [risk ratio 1.79 (1.48–2.16), P < 0.0001]. Within 5-year of diagnosis valve surgery was performed in 73% (70–75%) and 15% (13–17%) of severe and moderate DMR and in only 26% (19–34%) and 6% (4–8%) of severe and moderate FTR. Valvular surgery improved outcome without alleviating completely higher mortality associated with FTR (P < 0.0001).Conclusion In this large DMR cohort, FTR was frequent and causally, not only linked to PHTN but also to other factors, particularly AFib. Higher FTR severity is associated at diagnosis with more severe clinical presentation. Long term, FTR is independently of all confounders, associated with considerably worse mortality. Functional tricuspid regurgitation moderate and even severe is profoundly undertreated. Thus careful assessment, consideration for tricuspid surgery, and testing of new transcatheter therapy is warranted.
      PubDate: Thu, 16 Apr 2020 00:00:00 GMT
      DOI: 10.1093/eurheartj/ehaa192
      Issue No: Vol. 41, No. 20 (2020)
       
  • The tricuspid tragedy: from Cinderella to celebrity
    • Authors: Nickenig G; Vogelhuber J.
      Pages: 1930 - 1931
      Abstract: This editorial refers to ‘Functional tricuspid regurgitation of degenerative mitral valve disease: a crucial determinant of survival††’ by B. Essayagh et al., on page 1918.
      PubDate: Sun, 26 Apr 2020 00:00:00 GMT
      DOI: 10.1093/eurheartj/ehaa255
      Issue No: Vol. 41, No. 20 (2020)
       
  • High low-density lipoprotein levels and high risk of aortic stenosis
    • Authors: Greve A.
      Pages: 1941 - 1941
      Abstract: This commentary refers to ‘Plasma lipids and risk of aortic valve stenosis: a Mendelian randomization study’ by M. Nazarzadeh et al., doi: 10.1093/eurheartj/ehaa070.
      PubDate: Thu, 07 May 2020 00:00:00 GMT
      DOI: 10.1093/eurheartj/ehaa296
      Issue No: Vol. 41, No. 20 (2020)
       
  • Limitations of subgroup analysis of underpowered clinical trials for
           making causal inference about treatment effects
    • Authors: Nazarzadeh M; Rahimi K.
      Pages: 1942 - 1942
      Abstract: This commentary refers to ‘High low-density lipoprotein levels and high risk of aortic stenosis’, by A.M. Greve, on page 1941.
      PubDate: Thu, 07 May 2020 00:00:00 GMT
      DOI: 10.1093/eurheartj/ehaa355
      Issue No: Vol. 41, No. 20 (2020)
       
  • Rescuing from conduction disturbances with recapturable self-expanding
           transcatheter heart valve system
    • Authors: Ohno Y; Sakai K, Nakazawa G, et al.
      Pages: 1929 - 1929
      Abstract: An 88-year-old Japanese woman presented with New York Heart Association (NYHA) Class III heart failure symptom despite maximum medical therapy. Echocardiography showed severe aortic stenosis and heart team decision was to perform transfemoral transcatheter aortic valve implantation (TAVI) due to high surgical risk. Baseline electrocardiogram (ECG) showed normal sinus rhythm with no bundle branch block. Computed tomography showed annulus perimeter of 67.5 mm, therefore, CoreValve Evolut PRO 26 mm (Medtronic Inc., Galway, Ireland) was chosen. During the first attempt, at the point of no recapture, the valve was considered too shallow, i.e. 1 mm at non-coronary cusp (NCC), 4 mm at left coronary cusp (LCC) (Panel A) which lead to first recapture. Electrocardiogram did not change from the baseline (Panel B). During the second attempt, the valve was 6 mm at NCC, 6 mm at LCC (Panel C) and ECG showed complete atrioventricular block which lead to second recapture (Panel D). During the third attempt, the valve was 3 mm at NCC, 6 mm at LCC (Panel E) and ECG showed recovery of sinus rhythm with complete left bundle branch block (cLBBB) (Panel F). Depth was appropriate, therefore, the valve was fully released. Final angiography showed trivial perivalvular leakage (PVL) with the depth 4 mm at NCC, 6 mm at LCC (Panel G) and by the end of the procedure, ECG showed sinus rhythm and recovery from cLBBB (Panel H). Post-procedural echocardiography showed excellent haemodynamics with trivial PVL. Patient was discharged 3 days after the procedure and clinically remains asymptomatic 9 months after the procedure with ECG of sinus rhythm and narrow QRS complex.
      PubDate: Tue, 04 Jun 2019 00:00:00 GMT
      DOI: 10.1093/eurheartj/ehz360
      Issue No: Vol. 41, No. 20 (2019)
       
  • Uncertainties and challenges in surgical and transcatheter tricuspid valve
           therapy: a state-of-the-art expert review
    • Authors: Chang C; Veen K, Hahn R, et al.
      Pages: 1932 - 1940
      Abstract: AbstractTricuspid regurgitation (TR) is a frequent and complex problem, commonly combined with left-sided heart disease, such as mitral regurgitation. Significant TR is associated with increased mortality if left untreated or recurrent after therapy. Tricuspid regurgitation was historically often disregarded and remained undertreated. Surgery is currently the only Class I Guideline recommended therapy for TR, in the form of annuloplasty, leaflet repair, or valve replacement. As growing experience of transcatheter therapy in structural heart disease, many dedicated transcatheter tricuspid repair or replacement devices, which mimic well-established surgical techniques, are currently under development. Nevertheless, many aspects of TR are little understood, including the disease process, surgical or interventional risk stratification, and predictors of successful therapy. The optimal treatment timing and the choice of proper surgical or interventional technique for significant TR remain to be elucidated. In this context, we aim to highlight the current evidence, underline major controversial issues in this field and present a future roadmap for TR therapy.
      PubDate: Wed, 11 Sep 2019 00:00:00 GMT
      DOI: 10.1093/eurheartj/ehz614
      Issue No: Vol. 41, No. 20 (2019)
       
  • Mitral chordal rupture by Impella 5.0 in a patient with fulminant
           myocarditis and inflammation of mitral chordae
    • Authors: Yamamoto M; Yoneyama F, Kato H, et al.
      Pages: 1943 - 1943
      Abstract: A 26-year-old man was admitted with new-onset acute heart failure. Echocardiography showed severe biventricular systolic dysfunction with trivial mitral regurgitation (MR). Right ventricular endomyocardial biopsy showed heavy inflammatory cellular infiltrate dominated by lymphocytes (Panel A, scale bar: 100 μm). He was diagnosed with lymphocytic fulminant myocarditis. Due to cardiogenic shock with multiple organ failure, Impella 2.5 and veno-arterial peripheral extracorporeal membrane oxygenation (VA ECMO) were immediately initiated. The haemodynamic profile improved. However, cardiac function did not improve enough to withdraw the mechanical support. Therefore, we exchanged Impella 2.5 for Impella 5.0 after 7 days, for long-term mechanical support. Echocardiography showed trivial MR after 8 days from the exchange; however, the next day, massive MR due to chordal rupture of the posterior leaflet suddenly appeared (Panels B and C; see Supplementary material onlineSupplementary material online, Videos S1 and S2). He underwent mitral valve replacement and induction of central ECMO for post-operative circulatory support. Intraoperative findings revealed ruptured chordae of the posterior leaflet (Panel D). Pathological findings showed inflammatory cell infiltration in the mitral valve and chordae (Panels E and F, scale bar: 200 μm). His cardiac function gradually improved and central ECMO could be withdrawn after post-operative 11 days. He was finally discharged from the hospital. Mitral chordal rupture by Impella is a relatively rare complication. However, vulnerability of the mitral valve leaflet and chordae due to inflammation could be a potential risk for Impella-related chordal rupture. Our experience suggests the need for closer monitoring of Impella, especially in patients with fulminant myocarditis.
      PubDate: Tue, 24 Sep 2019 00:00:00 GMT
      DOI: 10.1093/eurheartj/ehz675
      Issue No: Vol. 41, No. 20 (2019)
       
  • Paravalvular leakage due to ring dehiscence after mitral valve-in-ring
           therapy: mechanisms and percutaneous treatment
    • Authors: Rumpf P; Michel J, Xhepa E, et al.
      Pages: 1944 - 1944
      Abstract: A 78-year-old man presented with congestive heart failure 14 years after surgical mitral valve repair (34-mm Edwards Physioring II). After stabilization, our heart team recommended a VIR procedure due to severe mitral valvular insufficiency.
      PubDate: Tue, 05 Nov 2019 00:00:00 GMT
      DOI: 10.1093/eurheartj/ehz763
      Issue No: Vol. 41, No. 20 (2019)
       
  • Transcatheter aortic valve implantation with a new generation mechanically
           expanding valve in a patient with a protruding coronary stent into the
           sinus of Valsalva: the ‘reversed-chimney’ technique
    • Authors: Abdel-Wahab M; Kitamura M, Holzhey D, et al.
      Pages: 1945 - 1945
      Abstract: A 79-year-old male patient was referred to our institution for transcatheter aortic valve implantation. Six days earlier, a drug-eluting stent (3.5 × 28 mm) was implanted at the ostium of the right coronary artery (RCA) for severe ostial stenosis. Computed tomography (CT) evaluation revealed an 8 mm long protrusion of the stent into the sinus of Valsalva (Panels A–C). The height of the RCA from the aortic annulus was 15 mm (Panel B). To avoid stent crush or deformation, a new generation mechanically expanding valve (LOTUS Edge 25 mm, Boston Scientific, MA, USA) was selected because of its short height (19 mm), the possibility to avoid balloon dilatation and its complete repositionability. First, the protruding stent was engaged with a 6-Fr Judkins right 3.5 guiding catheter, and a guide-catheter-extension (GuideLiner, Teleflex, PA, USA) was introduced into the RCA over a 3.0 × 20 mm balloon. The LOTUS Edge valve was then positioned at 2 mm depth from the annulus plane; however, aortic root angiography suggested the upper edge of the valve might be in contact with the coronary stent. The valve was repositioned at 4 mm depth, appeared to be below the coronary stent, and was then successfully deployed (Panel E, Supplementary material onlineSupplementary material online, Videos S1 and S2). To correct possible stent deformation by contact during valve deployment, the RCA stent was sequentially dilated with 3.0- and 3.5-mm balloons (Panel F). Final angiography demonstrated no paravalvular leakage (Panel G, Supplementary material onlineSupplementary material online, Video S3). A follow-up CT showed the transcatheter valve immediately below the RCA stent with no stent fracture and slight upward deformation, with a relationship between valve and stent resembling the chimney or snorkelling technique for coronary protection, though performed in a reversed order (Panels H and I).
      PubDate: Tue, 24 Sep 2019 00:00:00 GMT
      DOI: 10.1093/eurheartj/ehz676
      Issue No: Vol. 41, No. 20 (2019)
       
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 3.230.154.129
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-